Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Kaoru Kubota"'
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Autor:
Tsuneo Shimokawa, Hiroaki Okamoto, Ryunosuke Machida, Yuki Misumi, Yukio Hosomi, Yasuto Yoneshima, Hiroshi Tanaka, Kyoichi Okishio, Junichi Simizu, Koichi Goto, Hiroaki Akamatsu, Kaoru Kubota, Kazuhiko Nakagawa, Hidehito Horinouchi, Masahiko Ando, Tomoko Kataoka, Yuichiro Ohe
Publikováno v:
Lung Cancer. 181:107195
Autor:
Noboru Yamamoto, Kaoru Kubota, Tomohide Tamura, Yutaka Fujiwara, Yuichiro Ohe, Hiroshi Nokihara, Hidehito Horinouchi, Shintaro Kanda, Hideo Kunitoh, Ikuo Sekine
Publikováno v:
Lung Cancer. 89:287-293
Objectives In the first-line treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has been shown to yield a longer progression-free survival (PFS) rate tha
Autor:
Masahiro Seike, Yoshinobu Saito, Kouzui Kida, Nariaki Kokuho, Akihiko Gemma, Yuji Minegishi, Arata Azuma, Akihiko Miyanaga, Rintaro Noro, Kaoru Kubota, Yukiko Miura, Masaru Matsumoto
Publikováno v:
Lung Cancer. 85:258-263
Background Combined pulmonary fibrosis and emphysema (CPFE) patients may be at significantly increased risk of lung cancer compared with either isolated emphysema or pulmonary fibrosis patients. Acute exacerbation (AE) of interstitial lung disease ca
Autor:
Hironobu Ohmatsu, Seiji Niho, Yutaka Nishiwaki, Kiyotaka Yoh, Nagahiro Saijo, Young Hak Kim, Tatsuya Nagano, Koichi Goto, Yoichi Naito, Kaoru Kubota
Publikováno v:
Lung Cancer. 69:315-318
There has been no report about re-challenge chemotherapy (RC) consisting of the same regimen as first-line chemotherapy in non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the efficacy of RC as second-line chemotherapy in pat
Autor:
Atsushi Ochiai, Genichiro Ishii, Kaoru Kubota, Michiaki Mishima, Shuji Ota, Koichi Goto, Yukinori Murata, Young Hak Kim, Yutaka Nishiwaki, Nagahiro Saijo
Publikováno v:
Lung Cancer. 65:105-111
Summary Background ATP-binding cassette (ABC) transporter and DNA excision repair proteins play a pivotal role in the mechanisms of drug resistance. The aim of this study was to investigate the expression of ABC transporter and DNA excision repair pr
Autor:
Kaoru Kubota, Kiyotaka Yoh, Seiji Niho, Yutaka Nishiwaki, Koichi Goto, Nagahiro Saijo, Hironobu Ohmatsu, Ryutaro Kakinuma
Publikováno v:
Lung Cancer. 55:337-341
Summary Vinorelbine is a moderate vesicant that is well known to cause local venous toxicity such as drug induced-phlebitis. We conducted a prospective randomized trial to determine whether a 1-min bolus injection (1 min bolus) of vinorelbine reduced
Autor:
Kiyoyuki Furuse, Hisanobu Niitani, M Ogawara, Yutaka Nishiwaki, Akira Sakuma, Kaoru Kubota, Masaaki Kawahara, Etuo Kinuwaki, Masakichi Motomiya
Publikováno v:
Lung Cancer. 11:385-391
To evaluate the effectiveness of vinorelbine (NVB) in patients with non-small cell lung cancer (NSCLC), a late Phase II study was conducted. A total of 80 patients with Stage III or IV NSCLC who had no previous therapy were entered into the study. Se
Autor:
E Moriyama, Yuichiro Ohe, Kaoru Kubota, R. Kakinuma, H Uramoto, Nagahiro Saijo, Seiji Niho, Yutaka Nishiwaki, Koichi Goto, Hideo Kunitoh, Yukio Hosomi, Hironobu Ohmatsu, Taketoshi Matsumoto
Publikováno v:
Lung Cancer. 29:61-62
Autor:
Yutaka Nishiwaki, Hironobu Ohmatsu, Koichi Goto, E Moriyama, Yukio Hosomi, H Uramoto, R. Kakinuma, M Nomura, Taketoshi Matsumoto, Seiji Niho, Tetsu Shinkai, Kaoru Kubota
Publikováno v:
Lung Cancer. 29:86-87